Anti-radiation polypeptide and application thereof

By acylation of TP508 polypeptide into rings and using Fmoc solid phase synthesis method, anti-radiation polypeptides with stronger radiation resistance and better drug properties were prepared, solving the protection limitations and toxic side effects of existing anti-radiation drugs. , prolongs the survival of mice after radiation and provides a new treatment plan for radiation damage.

CN118910022AActive Publication Date: 2024-11-08ARMY MEDICAL UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411137689.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-19
Publication Date
2024-11-08
Estimated Expiration
2044-08-19

AI Technical Summary

Technical Problem

Existing anti-radiation drugs have protection limitations, potential toxic side effects, high prices and strict usage conditions, making it difficult to meet the efficient, safe, economical and convenient radiation protection needs of clinical practice and emergency response.

Method used

By acylation of the TP508 polypeptide into a ring, the radiation-resistant polypeptide was prepared by Fmoc solid phase synthesis method, and its amino acid sequence was optimized to improve radiation-resistant effect and drug properties.

Benefits of technology

The survival of mice after radiation is extended, and it provides stronger radiation resistance and better drug properties, providing a new solution for radiation damage treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910022A_ABST
    Figure CN118910022A_ABST
Patent Text Reader

Abstract

The invention discloses an anti-radiation polypeptide and application thereof, the anti-radiation polypeptide is obtained by acylating the head and the tail of TP508 into a ring, and the amino acid sequence of the TP508 is AGYKPDEGKRGDACEGDSGGPFV. According to the invention, TP508 is modified to obtain the polypeptide drug with stronger anti-radiation effect and better druggability. The polypeptide can prolong the lifetime of a mouse after radiation, can be applied to treatment for relieving radiation injury, and provides a new scheme and a new idea for radiation treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine and provides an anti-radiation polypeptide and application thereof. Background Art

[0002] Radiation protectors are drugs used to prevent, reduce or treat ionizing radiation damage. Depending on the duration of use, they are divided into radiation protectors, radiation modulators and radiation therapeutic agents. The core mechanism of radiation protectors is to inhibit radiation-induced cell or tissue damage, enhance the body's ability to resist radiation exposure, and promote the repair of radiation-induced tissue damage. Currently on the market, radiation protectors include amifostine, palifermin, filgrastim, polyethylene glycol filgrastim, sargramostim, radionuclide elimination agents, etc. Radiation protectors that are undergoing clinical trials include eltrombopag and HemaMax TM , pharmacological doses of ascorbic acid, entommod, genistein, beclomethasone dipropionate, etc. These radiation protectors can inhibit the damage caused by radiation to a certain extent. However, some radiation protectors have protection limitations. Their potential toxic side effects, high prices and strict conditions of use suggest that new anti-radiation drugs need to be developed in order to achieve more efficient, safe, economical and convenient radiation protection solutions to meet the higher demands of clinical practice and emergency response.

[0003] The prior art closest to the present invention is peptide TP508 (AGYKPDEGKRGDACEGDSGGPFV) (Kantara, C., et al., Novel regenerative peptide TP508 mitigates radiation-induced gastrointestinal damage by activating stem cells and preserving cryptintegrity. Lab Invest, 2015. 95 (11): p. 1222-33.). TP508 is a 23 amino acid non-proteolytic thrombin peptide that represents a portion of the receptor binding region of the thrombin molecule. TP508 can reduce the effects of radiation on human endothelial cells, restore endothelial NO production, angiogenesis and accelerate the repair of radiation-induced DNA double-strand breaks.

[0004] The present invention mainly modifies TP508 to obtain a polypeptide drug with stronger anti-radiation effect and better drugability. Summary of the invention

[0005] In view of this, the object of the present invention is to provide an anti-radiation polypeptide and its application to prolong the growth period of irradiated mice.

[0006] To achieve the above object, the present invention provides the following technical solutions:

[0007] 1. An anti-radiation polypeptide is obtained by acylation of TP508 into a ring, wherein the amino acid sequence of TP508 is: AGYKPDEGKRGDACEGDSGGPFV, as shown in SEQ ID NO.1.

[0008] 2. The preparation method of the aforementioned radiation-resistant peptide comprises differentially protecting and removing the α-amino group of the N-terminal amino acid of TP508, and then condensing the α-amino group with the C-terminal carboxyl group of the peptide to realize a head-to-tail cyclic peptide.

[0009] As one of the preferred technical solutions, the Fmoc solid phase synthesis method is adopted.

[0010] As one of the further preferred technical solutions, the first amino acid at the C-terminus of the polypeptide is first connected to a 2-CTC-resin that is sensitive to weak acids, and then the amino acids are condensed in sequence from the C-terminus to the N-terminus according to the sequence of the polypeptide; the amino acids are protected by an Fmoc (9-fluorenylmethoxycarbonyl) group at their amino termini, and are coupled with a growing chain (a polypeptide chain gradually constructed on a resin support; amino acid residues are gradually added from the C-terminus (carboxyl terminus) to the N-terminus (amino terminus) until the expected sequence length is reached) after activation at the carboxylic acid terminus; the Fmoc group is then removed by piperidine treatment and the process is repeated.

[0011] As one of the further preferred technical solutions, after the peptide is assembled, it can be removed from the resin by treating it with a 2% trifluoroacetic acid (TFA) aqueous solution by volume; at this time, the protecting groups on the amino acid side chains are retained, and only the amino group at the N-terminus and the carboxyl group at the C-terminus of the polypeptide are exposed, thereby obtaining a crude fully protected linear peptide; after the crude fully protected linear peptide is dissolved, a condensing agent is used to condense the exposed amino group at the N-terminus and the carboxyl group at the C-terminus of the polypeptide into a fully protected cyclic peptide, and then a 95% TFA aqueous solution is used to remove all the side chain protecting groups of the obtained fully protected cyclic peptide to obtain the target cyclic peptide. The polypeptide is purified by high performance liquid chromatography (HPLC) to remove by-products and unreacted substances.

[0012] HPLC chromatographic conditions:

[0013] Chromatographic column: kromasil C18-5 column (4.6*150mm); mobile phase A is 0.1% trifluoroacetic acid acetonitrile solution by volume, B is 0.1% trifluoroacetic acid aqueous solution by volume, gradient elution (0.01min, 5% A 95% B, 25.0min, 75% A 25% B, 30min, 90% A 10% B; changes in mobile phase are all volume percentages); flow rate 1.0mL / min; detection wavelength 214nm; injection volume 20ul.

[0014] MS mass spectrometry conditions: expected MS is 2294.47; flow rate is 0.2 mL / min; running time is 1 min; buffer A is a 0.1% by volume formic acid aqueous solution, and buffer B is a 0.1% by volume formic acid acetonitrile solution.

[0015] 3. Use of the aforementioned anti-radiation polypeptide in the preparation of anti-radiation drugs.

[0016] The beneficial effects of the present invention are:

[0017] The prior art closest to the present invention is peptide TP508 (AGYKPDEGKRGDACEGDSGGPFV) (Kantara, C., et al., Novel regenerative peptide TP508 mitigates radiation-induced gastrointestinal damage by activating stem cells and preserving cryptintegrity. Lab Invest, 2015. 95 (11): p. 1222-33.). TP508 is a 23 amino acid non-proteolytic thrombin peptide that represents a portion of the receptor binding region of the thrombin molecule. TP508 mitigates the effects of radiation on human endothelial cells, restores endothelial NO production, angiogenesis, and accelerates the repair of radiation-induced DNA double-strand breaks.

[0018] The present invention mainly modifies TP508 to obtain a polypeptide drug with stronger anti-radiation effect and better drugability. The polypeptide can prolong the survival of mice after radiation, can be used to alleviate radiation damage treatment, and provide a new solution and new idea for radiation therapy.

[0019] Other advantages, objectives and features of the present invention will be described in the following description to some extent, and to some extent, will be obvious to those skilled in the art based on the following examination and study, or can be taught from the practice of the present invention. The objectives and other advantages of the present invention can be realized and obtained through the following description. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] In order to make the purpose, technical solutions and advantages of the present invention more clear, the present invention will be described in detail below in conjunction with the accompanying drawings, wherein:

[0021] Figure 1 This is the result of HPLC analysis of Anti-N peptide;

[0022] Figure 2 This is the result of MS analysis of Anti-N peptide;

[0023] Figure 3 The date of death of irradiated Balbc mice after the anti-radiation peptide acted on them;

[0024] Figure 4 This is the survival curve of irradiated Balbc mice after the anti-radiation peptide acted on them;

[0025] Figure 5 The date of death of irradiated Balbc mice after the anti-radiation peptide acted on them;

[0026] Figure 6 This is the survival curve of irradiated Balbc mice after the anti-radiation peptide acted on them;

[0027] Figure 7 It is the structure of Anti-N peptide. DETAILED DESCRIPTION

[0028] The present invention will be further described below in conjunction with specific implementation modes.

[0029] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.

[0030] Embodiment 1:

[0031] Preparation of Anti-radiation Peptide (Anti-N Peptide)

[0032] TP508 (AGYKPDEGKRGDACEGDSGGPFV) was acylated head-to-tail to form a ring ( Figure 7 ).

[0033] Using the Fmoc solid phase synthesis method, the first amino acid at the C-terminus of the polypeptide is connected to the weakly acid-sensitive 2-CTC-resin, and then the amino acids are condensed in sequence from the C-terminus to the N-terminus according to the sequence of the polypeptide; the amino acid is protected by the Fmoc (9-fluorenylmethoxycarbonyl) group at its amino terminus and coupled to the growing chain after activation of the carboxylic acid terminus; the Fmoc group is then removed by piperidine treatment and the process is repeated.

[0034] After the peptide is assembled, it can be removed from the resin by treating it with a 2% trifluoroacetic acid (TFA) aqueous solution; at this time, the protecting groups on the amino acid side chains are retained, and only the amino group at the N-terminus and the carboxyl group at the C-terminus of the polypeptide are exposed to obtain a crude fully protected linear peptide; after the crude fully protected linear peptide is dissolved, a condensing agent is used to condense the exposed amino group at the N-terminus and the carboxyl group at the C-terminus of the polypeptide into a fully protected cyclic peptide, and then a 95% TFA aqueous solution is used to remove all the side chain protecting groups of the obtained fully protected cyclic peptide to obtain the target cyclic peptide. The polypeptide is purified by high performance liquid chromatography (HPLC) to remove by-products and unreacted substances (such as Figure 1 shown).

[0035] HPLC chromatographic conditions:

[0036] Chromatographic column: kromasil C18-5 column (4.6*150mm); mobile phase A is 0.1% trifluoroacetic acid acetonitrile solution by volume, B is 0.1% trifluoroacetic acid aqueous solution by volume, gradient elution (0.01min, 5% A 95% B, 25.0min, 75% A 25% B, 30min, 90% A 10% B; changes in mobile phase are all volume percentages); flow rate 1.0mL / min; detection wavelength 214nm; injection volume 20ul.

[0037] The molecular weight and composition of the peptides were determined by mass spectrometry (MS). Figure 2 ), MS mass spectrometry conditions: expected MS is 2294.47; flow rate is 0.2 mL / min; running time is 1 min; buffer A is a 0.1% by volume formic acid aqueous solution, and buffer B is a 0.1% by volume formic acid acetonitrile solution.

[0038] Embodiment 2:

[0039] In vivo peptide therapy test in mice

[0040] Balbc male mice aged 10 to 12 weeks (Chongqing Tengxin Bill Experimental Animal Sales Co., Ltd.) were irradiated with an X-ray irradiator at a dose of 6Gy (1.252Gy / min). After irradiation, the mice were given drugs and their survival period was observed.

[0041] Experiment 1: Mice were randomly assigned to four treatment groups (15 mice in each group): saline treatment group (Ctrl), TP508 treatment group, radiation peptide (Anti-N) treatment group and radiation peptide (802) treatment group. 1 hour after radiation, mice were injected with 0.035mg / ml peptide (control group was injected with saline), and the survival time of mice was observed. The results are as follows Figure 3 , Figure 4As shown, the modified anti-radiation peptide (Anti-N) can prolong the survival of mice. The amino acid sequence of the radiation peptide (802) is AGYKPDEGK (gamma-Glu-C16) RGDACEGSDGGPFV-NH2, and the amino acid sequence of TP508 is

[0042] AGYKPDEGKRGDACEGDSGGPFV.

[0043] Experiment 2: To further compare the effects of TP508 and Anti-N, an irradiation experiment was performed again. Mice were randomly assigned to three treatment groups (15 mice in each group): saline treatment group (Ctrl), TP508 treatment group, and irradiated peptide (Anti-N). One hour after irradiation, mice were injected with 0.05 mg / ml peptide (control group was injected with saline), and the survival time of mice was observed. The results are as follows Figure 5 , Figure 6 shown.

[0044] Balbc male mice were administered 1 hour after 6Gy X-ray irradiation (n=15 per group), group 1 was treated with saline, group 2 was treated with TP508, and group 3 was treated with the optimized anti-radiation peptide (Anti-N). After the mice were injected with 0.05mg / ml peptide (the control group was injected with saline), the death date of the mice was observed ( Figure 5 ) and lifetime( Figure 6 ). The results showed that the modified anti-radiation peptide (Anti-N) could prolong the survival of mice and its effect was better than TP508.

[0045] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the purpose and scope of the technical solution, which should be included in the scope of the claims of the present invention.

Claims

1. A radiation-resistant polypeptide, characterized in that: It is obtained by acylation of TP508 from head to tail to form a ring. The amino acid sequence of TP508 is: AGYKPDEGKRGDACEGDSGGPFV, as shown in SEQ ID NO.

1.

2. A method for preparing an anti-radiation polypeptide according to claim 1, comprising differentially protecting and removing the α-amino group of the N-terminal amino acid of TP508, and then condensing the α-amino group with the C-terminal carboxyl group of the polypeptide to achieve a head-to-tail cyclic peptide.

3. The preparation method according to claim 2, characterized in that: Fmoc solid phase synthesis was used.

4. The preparation method according to claim 3, characterized in that: The first amino acid at the C-terminus of the peptide is first connected to the weakly acid-sensitive 2-CTC-resin, and then the amino acids are condensed in order from the C-terminus to the N-terminus according to the sequence of the peptide; the amino acids are protected by the Fmoc group at their amino termini and coupled to the growing chain after activation of the carboxylic acid termini; the Fmoc group is then removed by piperidine treatment and the process is repeated.

5. The preparation method according to claim 4, characterized in that: After the peptide is assembled, it is removed from the resin by treating it with a 2% by volume aqueous solution of trifluoroacetic acid; at this time, the protecting groups on the amino acid side chains are retained, and only the amino group at the N-terminus and the carboxyl group at the C-terminus of the polypeptide are exposed, thereby obtaining a crude fully protected linear peptide; after the crude fully protected linear peptide is dissolved, a condensing agent is used to condense the exposed amino group at the N-terminus and the carboxyl group at the C-terminus of the polypeptide into a fully protected cyclic peptide, and then a 95% by volume aqueous solution of TFA is used to remove all the side chain protecting groups of the obtained fully protected cyclic peptide to obtain the target cyclic peptide.

6. Use of the anti-radiation polypeptide according to claim 1 in the preparation of anti-radiation drugs.

Citation Information

Patent Citations

  • Ifbm's to promote attachment of target analytes

    CN101585865A

  • Biofunctional coatings

    US20060051396A1

  • Targeting anabolic drugs for accelerated fracture repair

    WO2019232283A1